Codexis licenses genomics life science enzyme portfolio to Alphazyme

Codexis (CDXS) has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme, part of Maravai LifeSciences (MRVI), for multiple enzymes in Codexis’ life science enzyme portfolio. The agreement includes licenses for the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes that were in development directed towards genomics and diagnostics applications prior to the company’s strategic shift announced in July 2023. Under the terms of the agreement, Codexis is eligible to receive sales-based royalties. Alphazyme collaborates with manufacturers of nucleic acid synthesis and detection platforms to produce custom enzyme formulations for the custom DNA and RNA molecules, genomic medicines and genetic testing markets. This license agreement marks another transaction in which Codexis is executing on its strategy to divest the company’s non-core assets following its strategic shift to focus on the growth of its Pharmaceutical Manufacturing business and Enzyme Catalyzed Oligonucleotide Synthesis manufacturing platform.